Adverum Biotechnologies IncNASDAQ:ADVM
- LAST PRICE7.7600
- TODAY'S CHANGE (%)-0.2400 (-3.0000%)
- Bid / Lots7.7000/ 10
- Ask / Lots8.1800/ 1
- Open / Previous Close8.1800 / 8.0000
- Day Range
- 52 Week Range
- Volume147,086
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ADVM |
|---|---|---|
| 09:32 ET | 2369 | 8.02 |
| 09:33 ET | 1151 | 8.035 |
| 09:35 ET | 100 | 8.04 |
| 09:39 ET | 100 | 8.045 |
| 09:42 ET | 1200 | 7.96 |
| 09:51 ET | 120 | 7.9147 |
| 09:57 ET | 100 | 7.955 |
| 10:11 ET | 289 | 7.9 |
| 10:13 ET | 100 | 7.97 |
| 10:20 ET | 200 | 7.91 |
| 10:26 ET | 200 | 7.955 |
| 10:29 ET | 1594 | 7.98 |
| 10:31 ET | 1324 | 7.965 |
| 10:36 ET | 1293 | 7.93 |
| 10:38 ET | 213 | 7.93 |
| 10:40 ET | 300 | 7.91 |
| 10:44 ET | 6268 | 7.875 |
| 10:45 ET | 100 | 7.85 |
| 10:47 ET | 100 | 7.85 |
| 10:49 ET | 100 | 7.85 |
| 10:51 ET | 100 | 7.85 |
| 10:54 ET | 300 | 7.85 |
| 10:56 ET | 1180 | 7.86 |
| 10:58 ET | 500 | 7.86 |
| 11:00 ET | 1611 | 7.87 |
| 11:02 ET | 1100 | 7.85 |
| 11:03 ET | 700 | 7.87 |
| 11:05 ET | 500 | 7.89 |
| 11:07 ET | 3219 | 7.85 |
| 11:14 ET | 100 | 7.8507 |
| 11:21 ET | 100 | 7.85 |
| 11:25 ET | 1184 | 7.885 |
| 11:27 ET | 100 | 7.885 |
| 11:30 ET | 100 | 7.885 |
| 11:34 ET | 300 | 7.85 |
| 11:36 ET | 768 | 7.88 |
| 11:39 ET | 100 | 7.865 |
| 11:41 ET | 500 | 7.8675 |
| 11:43 ET | 200 | 7.87 |
| 11:45 ET | 200 | 7.87 |
| 11:48 ET | 1000 | 7.85 |
| 11:50 ET | 100 | 7.85 |
| 11:52 ET | 1127 | 7.855 |
| 11:54 ET | 1300 | 7.85 |
| 11:56 ET | 3600 | 7.79 |
| 12:01 ET | 100 | 7.75 |
| 12:06 ET | 1648 | 7.805 |
| 12:35 ET | 5939 | 7.81 |
| 12:37 ET | 200 | 7.81 |
| 12:42 ET | 200 | 7.8 |
| 12:44 ET | 347 | 7.81 |
| 12:48 ET | 100 | 7.795 |
| 12:50 ET | 200 | 7.7768 |
| 12:51 ET | 142 | 7.8093 |
| 12:53 ET | 100 | 7.79 |
| 12:55 ET | 121 | 7.8099 |
| 12:57 ET | 3214 | 7.81 |
| 01:00 ET | 200 | 7.81 |
| 01:02 ET | 1100 | 7.79 |
| 01:04 ET | 108 | 7.76 |
| 01:06 ET | 151 | 7.78 |
| 01:11 ET | 183 | 7.7899 |
| 01:15 ET | 1700 | 7.77 |
| 01:24 ET | 916 | 7.76 |
| 01:26 ET | 1200 | 7.77 |
| 01:27 ET | 500 | 7.77 |
| 01:33 ET | 100 | 7.79 |
| 01:40 ET | 643 | 7.7999 |
| 01:45 ET | 100 | 7.76 |
| 01:54 ET | 843 | 7.8 |
| 02:00 ET | 100 | 7.77 |
| 02:03 ET | 100 | 7.77 |
| 02:07 ET | 100 | 7.77 |
| 02:12 ET | 4897 | 7.78 |
| 02:14 ET | 2548 | 7.75 |
| 02:23 ET | 4605 | 7.75 |
| 02:25 ET | 100 | 7.75 |
| 02:32 ET | 100 | 7.75 |
| 02:34 ET | 100 | 7.7524 |
| 02:36 ET | 100 | 7.75 |
| 02:38 ET | 189 | 7.75 |
| 02:43 ET | 453 | 7.76 |
| 02:45 ET | 100 | 7.75 |
| 02:50 ET | 1880 | 7.765 |
| 02:52 ET | 200 | 7.75 |
| 02:57 ET | 100 | 7.75 |
| 03:01 ET | 3931 | 7.75 |
| 03:03 ET | 146 | 7.75 |
| 03:06 ET | 2928 | 7.75 |
| 03:08 ET | 300 | 7.77 |
| 03:19 ET | 100 | 7.7624 |
| 03:21 ET | 100 | 7.76 |
| 03:24 ET | 2310 | 7.77 |
| 03:26 ET | 920 | 7.7888 |
| 03:28 ET | 2300 | 7.76 |
| 03:32 ET | 100 | 7.78 |
| 03:39 ET | 100 | 7.79 |
| 03:44 ET | 100 | 7.78 |
| 03:46 ET | 338 | 7.78 |
| 03:48 ET | 400 | 7.8 |
| 03:50 ET | 100 | 7.79 |
| 03:51 ET | 1408 | 7.77 |
| 03:53 ET | 1101 | 7.76 |
| 03:55 ET | 200 | 7.77 |
| 03:57 ET | 3990 | 7.76 |
| 04:00 ET | 19346 | 7.76 |
Nov 5, 2024
DJ Adverum Biotechnologies Is Maintained at Sector Perform by RBC Capital, from 11:28AM ET on Tuesday Nov 05, 2024 by Dow Jones
11:28AM ET on Tuesday Nov 05, 2024 by Dow Jones
Nov 4, 2024
Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones, from 4:39PM ET on Monday Nov 04, 2024 by Dow Jones
4:39PM ET on Monday Nov 04, 2024 by Dow Jones*DJ Adverum Biotechnologies 3Q Loss/Shr $1.30 >ADVM, from 4:39PM ET on Monday Nov 04, 2024 by Dow Jones
4:39PM ET on Monday Nov 04, 2024 by Dow Jones
Oct 16, 2024
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program, from 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 16, 2024 by Dow JonesPress Release: Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program, from 8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
8:00AM ET on Wednesday Oct 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Adverum Biotechnologies Inc | 166.4M | -1.0x | --- |
PepGen Inc | 163.3M | -1.5x | --- |
Actuate Therapeutics Inc | 171.1M | 0.0x | --- |
Skye Bioscience Inc | 173.2M | -1.4x | --- |
Generation Bio Co | 151.0M | -1.0x | --- |
Achieve Life Sciences Inc | 159.0M | -4.1x | --- |
Company Information
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection. It also developing an early-stage pipeline of gene therapy programs.
Contact Information
- Headquarters
- 100 Cardinal WayREDWOOD CITY, CA, United States 94063
- Phone
- 650-649-1004
- Fax
- 650-329-8151
Executives
- Independent Chairman of the Board
- Patrick Machado
- President, Chief Executive Officer, Director
- Laurent Fischer
- Chief Financial Officer
- Linda Rubinstein
- Chief Operating Officer
- Kishor Soparkar
- Chief Commercial Officer
- Jason Mitchell
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $166.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.96 |
EPS | $-7.99 |
Book Value | $8.23 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
